CN115003699A - 抗trem2抗体的使用方法 - Google Patents

抗trem2抗体的使用方法 Download PDF

Info

Publication number
CN115003699A
CN115003699A CN202080094665.7A CN202080094665A CN115003699A CN 115003699 A CN115003699 A CN 115003699A CN 202080094665 A CN202080094665 A CN 202080094665A CN 115003699 A CN115003699 A CN 115003699A
Authority
CN
China
Prior art keywords
antibody
amino acid
trem2
seq
acid sequence
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202080094665.7A
Other languages
English (en)
Chinese (zh)
Inventor
T·施瓦贝
I·塔西
A·罗森塔尔
龙华
S·V·萨拉查
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Ai Lituo
Original Assignee
Ai Lituo
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ai Lituo filed Critical Ai Lituo
Publication of CN115003699A publication Critical patent/CN115003699A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/75—Agonist effect on antigen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Genetics & Genomics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Molecular Biology (AREA)
  • Hospice & Palliative Care (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Psychiatry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
CN202080094665.7A 2019-12-05 2020-12-04 抗trem2抗体的使用方法 Pending CN115003699A (zh)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201962944298P 2019-12-05 2019-12-05
US62/944,298 2019-12-05
US202063005110P 2020-04-03 2020-04-03
US63/005,110 2020-04-03
PCT/US2020/063339 WO2021113655A1 (en) 2019-12-05 2020-12-04 Methods of use of anti-trem2 antibodies

Publications (1)

Publication Number Publication Date
CN115003699A true CN115003699A (zh) 2022-09-02

Family

ID=74046174

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202080094665.7A Pending CN115003699A (zh) 2019-12-05 2020-12-04 抗trem2抗体的使用方法

Country Status (10)

Country Link
US (1) US20230024528A1 (https=)
EP (1) EP3986937A1 (https=)
JP (1) JP2023505279A (https=)
KR (1) KR20220110537A (https=)
CN (1) CN115003699A (https=)
AU (1) AU2020397888A1 (https=)
CA (1) CA3158565A1 (https=)
IL (1) IL293386A (https=)
MX (1) MX2022006073A (https=)
WO (1) WO2021113655A1 (https=)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JOP20190248A1 (ar) 2017-04-21 2019-10-20 Amgen Inc بروتينات ربط مولد ضد trem2 واستخداماته
JP7745557B2 (ja) * 2020-02-24 2025-09-29 アレクトル エルエルシー 抗ｔｒｅｍ２抗体の使用方法
IL296992A (en) * 2020-04-03 2022-12-01 Alector Llc Methods for using anti-trem2 antibodies
WO2023192282A1 (en) 2022-03-28 2023-10-05 Denali Therapeutics Inc. Methods for treating brain glucose hypometabolism
WO2023192288A1 (en) 2022-03-28 2023-10-05 Denali Therapeutics Inc. Monovalent anti-trem2 binding molecules and methods of use thereof
AU2023373911A1 (en) * 2022-11-01 2025-05-15 Andreas Meier Anti-trem2 antibody and uses thereof
WO2025030887A1 (zh) * 2023-08-09 2025-02-13 成都优洛生物科技有限公司 抗trem2纳米抗体或其抗原结合片段及应用
WO2025046298A2 (en) 2023-09-01 2025-03-06 iTeos Belgium SA Anti-trem2 antibodies and methods of use
WO2025215252A1 (en) * 2024-04-12 2025-10-16 Ensocell Ltd Therapeutic agents and methods for targeting myeloid cell subtypes

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN107106679A (zh) * 2014-08-08 2017-08-29 艾利妥 抗trem2抗体及其使用方法
US20180186855A1 (en) * 2016-03-23 2018-07-05 Alector Llc Chimeric receptors and methods of use thereof
AU2017300040A1 (en) * 2016-07-22 2019-01-24 Deutsches Zentrum Für Neurodegenerative Erkrankungen E.V. (Dzne) TREM2 cleavage modulators and uses thereof
WO2019028292A1 (en) * 2017-08-03 2019-02-07 Alector Llc ANTI-TREM2 ANTIBODIES AND METHODS OF USE
US20190330335A1 (en) * 2015-10-06 2019-10-31 Alector Llc Anti-trem2 antibodies and methods of use thereof

Family Cites Families (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
GB8601597D0 (en) 1986-01-23 1986-02-26 Wilson R H Nucleotide sequences
US6548640B1 (en) 1986-03-27 2003-04-15 Btg International Limited Altered antibodies
GB8823869D0 (en) 1988-10-12 1988-11-16 Medical Res Council Production of antibodies
DE3920358A1 (de) 1989-06-22 1991-01-17 Behringwerke Ag Bispezifische und oligospezifische, mono- und oligovalente antikoerperkonstrukte, ihre herstellung und verwendung
DE69120146T2 (de) 1990-01-12 1996-12-12 Cell Genesys Inc Erzeugung xenogener antikörper
WO1996033735A1 (en) 1995-04-27 1996-10-31 Abgenix, Inc. Human antibodies derived from immunized xenomice
US6150584A (en) 1990-01-12 2000-11-21 Abgenix, Inc. Human antibodies derived from immunized xenomice
US6075181A (en) 1990-01-12 2000-06-13 Abgenix, Inc. Human antibodies derived from immunized xenomice
ATE158021T1 (de) 1990-08-29 1997-09-15 Genpharm Int Produktion und nützung nicht-menschliche transgentiere zur produktion heterologe antikörper
US5633425A (en) 1990-08-29 1997-05-27 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US5545806A (en) 1990-08-29 1996-08-13 Genpharm International, Inc. Ransgenic non-human animals for producing heterologous antibodies
US5661016A (en) 1990-08-29 1997-08-26 Genpharm International Inc. Transgenic non-human animals capable of producing heterologous antibodies of various isotypes
US5625126A (en) 1990-08-29 1997-04-29 Genpharm International, Inc. Transgenic non-human animals for producing heterologous antibodies
US5571894A (en) 1991-02-05 1996-11-05 Ciba-Geigy Corporation Recombinant antibodies specific for a growth factor receptor
US7018809B1 (en) 1991-09-19 2006-03-28 Genentech, Inc. Expression of functional antibody fragments
FI941572A7 (fi) 1991-10-07 1994-05-27 Oncologix Inc Anti-erbB-2-monoklonaalisten vasta-aineiden yhdistelmä ja käyttömenete lmä
ATE207080T1 (de) 1991-11-25 2001-11-15 Enzon Inc Multivalente antigen-bindende proteine
CA2372813A1 (en) 1992-02-06 1993-08-19 L.L. Houston Biosynthetic binding protein for cancer marker
US5789199A (en) 1994-11-03 1998-08-04 Genentech, Inc. Process for bacterial production of polypeptides
US5840523A (en) 1995-03-01 1998-11-24 Genetech, Inc. Methods and compositions for secretion of heterologous polypeptides
US5641870A (en) 1995-04-20 1997-06-24 Genentech, Inc. Low pH hydrophobic interaction chromatography for antibody purification
US5739277A (en) 1995-04-14 1998-04-14 Genentech Inc. Altered polypeptides with increased half-life
US5869046A (en) 1995-04-14 1999-02-09 Genentech, Inc. Altered polypeptides with increased half-life
WO1996034096A1 (en) 1995-04-28 1996-10-31 Abgenix, Inc. Human antibodies derived from immunized xenomice
AU7378096A (en) 1995-09-28 1997-04-17 Alexion Pharmaceuticals, Inc. Porcine cell interaction proteins
CA2722378C (en) 1996-12-03 2015-02-03 Amgen Fremont Inc. Human antibodies that bind tnf.alpha.
DK1034298T3 (da) 1997-12-05 2012-01-30 Scripps Research Inst Humanisering af murint antistof
GB9809951D0 (en) 1998-05-08 1998-07-08 Univ Cambridge Tech Binding molecules
US8981061B2 (en) 2001-03-20 2015-03-17 Novo Nordisk A/S Receptor TREM (triggering receptor expressed on myeloid cells) and uses thereof
CA2502413A1 (en) 2002-11-01 2004-05-21 The Regents Of The University Of Colorado, A Body Corporate Quantitative analysis of protein isoforms using matrix-assisted laser desorption/ionization time of flight mass spectrometry
CN101120021A (zh) 2004-12-31 2008-02-06 基因技术公司 结合br3的多肽及其用途
US7700099B2 (en) 2005-02-14 2010-04-20 Merck & Co., Inc. Non-immunostimulatory antibody and compositions containing the same
US20090220508A1 (en) 2006-03-15 2009-09-03 Alexion Pharmaceuticals, Inc. Treatment Of Paroxysmal Nocturnal Hemoglobinuria Patients By An Inhibitor Of Complement
UY30776A1 (es) 2006-12-21 2008-07-03 Medarex Inc Anticuerpos cd44
EP3124497B1 (en) 2007-09-14 2020-04-15 Adimab, LLC Rationally designed, synthetic antibody libraries and uses therefor
US8877688B2 (en) 2007-09-14 2014-11-04 Adimab, Llc Rationally designed, synthetic antibody libraries and uses therefor
KR102318383B1 (ko) 2010-07-16 2021-10-27 아디맵 엘엘씨 항체 라이브러리
JOP20190248A1 (ar) 2017-04-21 2019-10-20 Amgen Inc بروتينات ربط مولد ضد trem2 واستخداماته
WO2019055841A1 (en) 2017-09-14 2019-03-21 Denali Therapeutics Inc. ANTI-TREM2 ANTIBODIES AND METHODS OF USE
IL296992A (en) * 2020-04-03 2022-12-01 Alector Llc Methods for using anti-trem2 antibodies
JP2023536916A (ja) 2020-08-05 2023-08-30 ビジル・ニューロサイエンス・インコーポレイテッド Ｔｒｅｍ２アゴニストを使用した、コロニー刺激因子１受容体機能不全に関連する疾患の治療

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN107106679A (zh) * 2014-08-08 2017-08-29 艾利妥 抗trem2抗体及其使用方法
US20190330335A1 (en) * 2015-10-06 2019-10-31 Alector Llc Anti-trem2 antibodies and methods of use thereof
US20180186855A1 (en) * 2016-03-23 2018-07-05 Alector Llc Chimeric receptors and methods of use thereof
AU2017300040A1 (en) * 2016-07-22 2019-01-24 Deutsches Zentrum Für Neurodegenerative Erkrankungen E.V. (Dzne) TREM2 cleavage modulators and uses thereof
WO2019028292A1 (en) * 2017-08-03 2019-02-07 Alector Llc ANTI-TREM2 ANTIBODIES AND METHODS OF USE

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
ANDREW J.CATON: "Structural and functional implications of a restricted antibody response to a defined antigenic region on the influenza virus hemagglutinin", THE EMBO JOURNAL, vol. 5, no. 7, 1 July 1986 (1986-07-01) *

Also Published As

Publication number Publication date
KR20220110537A (ko) 2022-08-08
JP2023505279A (ja) 2023-02-08
MX2022006073A (es) 2022-08-04
EP3986937A1 (en) 2022-04-27
WO2021113655A1 (en) 2021-06-10
US20230024528A1 (en) 2023-01-26
IL293386A (en) 2022-07-01
AU2020397888A1 (en) 2022-06-09
CA3158565A1 (en) 2021-06-10

Similar Documents

Publication Publication Date Title
JP7554247B2 (ja) 抗ｔｒｅｍ２抗体及びその使用方法
JP7472056B2 (ja) ＦｃＲＨ５に対するヒト化親和性成熟抗体及び使用方法
CN115003699A (zh) 抗trem2抗体的使用方法
JP6669749B2 (ja) 抗ｔｒｅｍ２抗体及びその使用方法
CA2997960A1 (en) Anti-trem2 antibodies and methods of use thereof
CN119912569A (zh) 抗SIRP-β1抗体及其使用方法
JP7745557B2 (ja) 抗ｔｒｅｍ２抗体の使用方法
HK40079646A (en) Methods of use of anti-trem2 antibodies
RU2858085C2 (ru) ГУМАНИЗИРОВАННЫЕ АНТИТЕЛА И АНТИТЕЛА С СОЗРЕВШЕЙ АФФИННОСТЬЮ ПРОТИВ FcRH5 И СПОСОБЫ ИХ ПРИМЕНЕНИЯ
EA050276B1 (ru) Способы применения антител к trem2
HK40089688A (zh) 抗trem2抗体的使用方法
HK40019817B (en) Anti-trem2 antibodies and methods of use thereof
HK40019817A (en) Anti-trem2 antibodies and methods of use thereof
EA044134B1 (ru) Анти-trem2 антитела и способы их применения

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 40079646

Country of ref document: HK